Biogen Inc

BIIB

$259.95

+0.5% (1 year change)

Market Cap

$39.7 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$223.25 - $468.55

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

20.69x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $39.7 Billion
Enterprise Value $43.9 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +0.5%
52-Week High $468.55
52-Week Low $223.25
Beta 0.0
Outstanding Shares 147 Million
Avg 30 Day Volume 984 Thousand

Valuation

P/E Ratio 20.69
PEG -38.99
Earnings per Share $12.50
Price to Sales Ratio 3.47
Price to Book Ratio 3.56
Revenue to Enterprise Value 3.96
EBIT to Enterprise Value 24.78
Total Debt to Enterprise Value 0.17
Debt to Equity 0.68

Profitability

Revenue $11.1 Billion
Gross Profit $9.16 Billion
EBIT $1.77 Billion
Net Income $1.55 Billion
Profit Margin 13.93%
Quarterly Earnings Growth (YoY) -53.1%
Return on Equity 14.38%
Return on Assets 6.32%
Return on Invested Capital 8.39%

Insider trades

898 shares bought (1 transactions)

No sells

No purchases

11,119 shares sold (3 transactions)

No purchases

No sells

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Biogen Inc

CEO: Josephine Price

Employees: 7,300

Industry: Biological Product (except Diagnostic) Manufacturing

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

Similar stocks

AMGEN Inc.
Gilead Sciences, Inc.
Abbvie Inc
Pfizer Inc.
Johnson & Johnson
Acorda Therapeutics Inc
Sanofi - ADR
Bio-Rad Laboratories Inc. - Class A
Illumina Inc
Qiagen NV

News

Biogen (NASDAQ:BIIB) Price Target Lowered to $390.00 at Canaccord Genuity

Biogen (NASDAQ:BIIB) Price Target Lowered to $390.00 at Canaccord Genuity

Biogen (NASDAQ:BIIB) had its price target decreased by Canaccord Genuity from $423.00 to $390.00 in a research note issued to investors on Friday, The Fly reports. Canaccord Genuity currently has a...

 Dakota Financial News Dakota Financial News, 2 days ago
Q1 2022 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Lifted by Jefferies Financial Group

Q1 2022 EPS Estimates for Biogen Inc. (NASDAQ:BIIB) Lifted by Jefferies Financial Group

Biogen Inc. (NASDAQ:BIIB) Investment analysts at Jefferies Financial Group increased their Q1 2022 earnings per share (EPS) estimates for Biogen in a research note issued on Wednesday, October 20t...

 Dakota Financial News Dakota Financial News, 3 days ago
Jefferies Financial Group Comments on Biogen Inc.s FY2021 Earnings (NASDAQ:BIIB)

Jefferies Financial Group Comments on Biogen Inc.s FY2021 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) Equities research analysts at Jefferies Financial Group raised their FY2021 earnings estimates for shares of Biogen in a research report issued on Wednesday, October 20th...

 Dakota Financial News Dakota Financial News, 4 days ago